The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2021 | Comparing PACIFIC and GEMSTONE-301
Yi-Long Wu, MD, FACS, Guangdong General Hospital, Guangzhou, China, compares the PACIFIC (NCT02125461) and the GEMSTONE-301 (NCT03728556) clinical trials. Whilst the PACIFIC trial evaluates the efficacy of durvalumab in patients without disease progression after concurrent chemoradiotherapy (CRT), the GEMSTONE-301 trial evaluates sugemalimab in patients without disease progression after both concurrent and sequential CRT. In addition, patients were treated for a period of 12 months in the PACIFIC trial versus 24 months in the Gemstone-301 trial. Importantly, there were differences in the patients enrolled in the study in terms of stages and histology. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
Disclosures
Dr Wu reports advisory services for AstraZeneca, Boehringer Ingelheim, Novartis, Takeda; personal fees from AstraZeneca, Beigene, Boehringer Ingelheim, BMS, Eli Lilly, MSD, Pfizer, Roche, Sanofi; grants from AstraZeneca, Boehringer Ingelheim, BMS, Hengrui, and Roche, outside the submitted work.
